Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 14/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | TYMS | P04818 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18020599 | 0.86 | NSD2 (0.53) | NSD2TTRTYMS | |
| SCHEMBL16610066 | 0.84 | TYMS (0.53) | TYMS | |
| SCHEMBL18020594 | 0.83 | POLB (0.45) | NSD2TYMS | |
| SCHEMBL17986183 | 0.80 | NSD2 (0.45) | NSD2TTRTYMS | |
| SCHEMBL16610052 | 0.78 | NSD2 (0.46) | NSD2TTRTYMS | |
| SCHEMBL26744920 | 0.74 | TTR (0.65) | NSD2TTR | |
| SCHEMBL15274084 | 0.71 | TTR (0.59) | NSD2TTR | |
| SCHEMBL5171829 | 0.70 | TYMS (0.62) | TYMS | |
| SCHEMBL10064159 | 0.69 | CYP1A2 (0.49) | TYMS | |
| SCHEMBL9498944 | 0.68 | TTR (0.61) | NSD2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | UNIVERSITÄT ZU KOLN (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3049386-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| WO-2015044177-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | APC, BRCA1, VHL | NSD2 2192/4885TTR 679/4885TYMS 573/4885 |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | APC, BRCA1, VHL | NSD2 2192/4885TTR 679/4885TYMS 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.